Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01447719 · ClinicalTrials.gov registry record · Phase 3
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
A Phase 3 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
NCT01447719 is a Phase 3 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 110 participants.
The verdict
NCT01447719, a Phase 3 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
Study Summary
This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological assessment. The study will address the following specific aims: 1. To expand the number of subjects included in the A07 (NCT00857415) trial correlation analysis (measuring the correlation between the global visual rating of brain amyloid plaque density on an independent blinded read of the florbetapir F 18 PET scan and the cortical amyloid plaque density at autopsy as assessed by histopathology for subjects in the autopsy cohort). 2. To determine the sensitivity and specificity of an independent blinded visual read assessment of the florbetapir F 18 PET scan (Aβ+ or Aβ-) versus the final blinded neuropathological assessment made at autopsy.
Interventions
- DRUG florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01447719
The ClinicalTrials.gov registry entry for NCT01447719 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which florbetapir F 18 is the first listed.
NCT01447719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01447719 about?
NCT01447719 is a clinical study titled "Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07". This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological assessment. The study will address the following specific aims: 1. To expand the number of subjects inc...
What is the current status of trial NCT01447719?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2010-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01447719?
The interventions under investigation include: florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT01447719?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.